Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company based in Yantai, Shandong, China, established on July 4, 2008, and listed on March 31, 2022. The company focuses on antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies for therapeutic applications [2] - The company's main business revenue composition includes 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] - Rongchang Biopharmaceuticals aims to discover, develop, and commercialize innovative and distinctive first-in-class and best-in-class biopharmaceuticals to address significant unmet clinical needs in autoimmune diseases, oncology, and ophthalmic diseases [2] Financial Performance - For the first half of 2025, Rongchang Biopharmaceuticals achieved a revenue of 1.098 billion yuan, representing a year-on-year growth of 48.02%. However, the net profit attributable to shareholders was -450 million yuan, showing a year-on-year increase of 42.40% in losses [3] - As of June 30, 2025, the number of shareholders increased to 12,900, up by 90.69%, while the average circulating shares per person decreased by 47.56% to 12,595 shares [3] Stock Market Activity - On October 29, Rongchang Biopharmaceuticals' stock price fell by 2.02%, trading at 88.96 yuan per share with a total market capitalization of 50.139 billion yuan. The stock has increased by 195.45% year-to-date but has seen a decline of 6.46% in the last five trading days and 13.86% over the past 20 days [1] - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent occurrence on June 26, where it recorded a net buy of -137 million yuan [1] Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders include new entrants such as Hong Kong Central Clearing Limited, holding 9.3526 million shares, and Wanjiayouxuan, holding 5.9245 million shares. Other notable shareholders include ICBC Frontier Medical Stock A and Penghua Medical Technology Stock A, with varying changes in their holdings [4]

Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company focused on antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [2] - The company aims to discover, develop, and commercialize innovative and distinctive first-in-class and best-in-class biopharmaceuticals to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [2] - Main business revenue composition includes 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] Financial Performance - As of June 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.098 billion yuan, a year-on-year increase of 48.02% [3] - The net profit attributable to shareholders was -450 million yuan, reflecting a year-on-year growth of 42.40% [3] Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased to 12,900, up 90.69% from the previous period, while the average circulating shares per person decreased by 47.56% to 12,595 shares [3] - The stock price experienced a significant increase of 209.47% year-to-date, but has seen a decline of 6.07% in the last five trading days and 10.22% in the last 20 days [1] - Major shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 9.3526 million shares, and several new institutional investors have entered the top ten shareholders list [4]

Core Viewpoint - Rongchang Biopharmaceuticals has shown significant stock performance with a year-to-date increase of 220.29%, indicating strong market interest and potential growth in the biopharmaceutical sector [1][3]. Financial Performance - As of June 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.098 billion yuan, representing a year-on-year growth of 48.02% [3]. - The company recorded a net profit attributable to shareholders of -450 million yuan, which is a 42.40% increase compared to the previous period [3]. Stock Market Activity - On October 21, 2023, the stock price of Rongchang Biopharmaceuticals reached 96.44 yuan per share, with a trading volume of 351 million yuan and a turnover rate of 2.28% [1]. - The stock has experienced a net outflow of 28.82 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 12,900, a rise of 90.69% from the previous period [3]. - New significant shareholders include Hong Kong Central Clearing Limited and several mutual funds, indicating growing institutional interest [4]. Business Overview - Rongchang Biopharmaceuticals focuses on innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), monoclonal antibodies, and bispecific antibodies [2]. - The company aims to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology, with a revenue composition of 99.46% from product sales [2].

10月13日，荣昌生物涨1.61%，成交额8.52亿元。两融数据显示，当日荣昌生物获融资买入额1.10亿 元，融资偿还9098.19万元，融资净买入1878.68万元。截至10月13日，荣昌生物融资融券余额合计8.71 亿元。 融资方面，荣昌生物当日融资买入1.10亿元。当前融资余额8.69亿元，占流通市值的5.71%，融资余额 超过近一年90%分位水平，处于高位。 截至6月30日，荣昌生物股东户数1.29万，较上期增加90.69%；人均流通股12595股，较上期减少 47.56%。2025年1月-6月，荣昌生物实现营业收入10.98亿元，同比增长48.02%；归母净利润-4.50亿元， 同比增长42.40%。 机构持仓方面，截止2025年6月30日，荣昌生物十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股935.26万股，为新进股东。万家优选（161903）位居第五大流通股东，持股592.45万股， 为新进股东。工银前沿医疗股票A（001717）位居第六大流通股东，持股400.00万股，为新进股东。鹏 华医药科技股票A（001230）位居第七大流通股东，持股388.17万股，相比上期减少79. ...

Group 1 - On October 9, Rongchang Biopharma experienced a decline of 11.47% with a trading volume of 1.329 billion yuan, and the net financing purchase was 36.94 million yuan after a financing buy of 198 million yuan and a repayment of 161 million yuan [1] - As of October 9, the total balance of margin trading for Rongchang Biopharma was 828 million yuan, which accounts for 4.91% of its circulating market value, indicating a high level compared to the past year [1] - The company had a margin balance that exceeded the 90th percentile level over the past year, indicating a high level of borrowing activity [1] Group 2 - Rongchang Biopharma, established on July 4, 2008, and listed on March 31, 2022, focuses on innovative biopharmaceuticals, particularly in antibody-drug conjugates (ADC), fusion proteins, and monoclonal antibodies [2] - The company reported a revenue of 1.098 billion yuan for the first half of 2025, representing a year-on-year growth of 48.02%, while the net profit attributable to shareholders was -450 million yuan, an increase of 42.40% year-on-year [2] - The main revenue sources for the company include 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] Group 3 - As of June 30, 2025, the top ten circulating shareholders of Rongchang Biopharma included new entrants such as Hong Kong Central Clearing Limited and several mutual funds, indicating increased institutional interest [3] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 9.3526 million shares, while other new shareholders include Wanjiayouxuan and Huatai-PineBridge Innovation Healthcare Mixed A [3] - Some existing shareholders, such as Penghua Medical Technology Stock A and China Bank Innovation Medical Mixed A, have reduced their holdings, reflecting a shift in institutional positions [3]

9月25日，荣昌生物涨5.02%，截至发稿，报110.17元/股，成交2.19亿元，换手率1.24%，总市值620.93 亿元。 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业务涉及公司是一家具有全球 化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及 双抗等治疗性抗体药物领域。公司致力于发现、开发与商业化创新、有特色的同类首创(first-in-class)与 同类最佳(best-in-class)生物药,以创造药物临床价值为导向,为自身免疫疾病、肿瘤疾病、眼科疾病等重 大疾病领域提供安全、有效、可及的临床解决方案,以满足大量尚未被满足的临床需求。主营业务收入 构成为：销售商品99.46%，出售材料0.38%，租赁服务0.16%。 从基金十大重仓股角度 数据显示，嘉合基金旗下1只基金重仓荣昌生物。嘉合锦鹏添利混合A（008905）二季度持有股数20万 股，占基金净值比例为1.69%，位居第八大重仓股。根据测算，今日浮盈赚取约105.4万 ...

Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company based in Yantai, Shandong, China, established on July 4, 2008, and listed on March 31, 2022. The company focuses on antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The company aims to discover, develop, and commercialize innovative first-in-class and best-in-class biopharmaceuticals to address significant unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [1] - The main revenue sources for the company are product sales (99.46%), material sales (0.38%), and leasing services (0.16%) [1] Market Performance - On September 19, Rongchang Biopharmaceuticals' stock fell by 5.02%, trading at 99.35 CNY per share, with a total transaction volume of 659 million CNY and a turnover rate of 3.98%. The company's total market capitalization is approximately 55.994 billion CNY [1] Fund Holdings - According to data, one fund under Jiashi Fund holds a significant position in Rongchang Biopharmaceuticals. Jiashi Xinhe One-Year Holding Period Mixed A (008664) held 14,900 shares in the second quarter, accounting for 0.38% of the fund's net value, ranking as the eighth-largest holding [2] - The fund has experienced a floating loss of approximately 78,200 CNY today [2] Fund Manager Profile - The fund manager of Jiashi Xinhe One-Year Holding Period Mixed A is Yang Yechao, who has been in the position for 9 years and 300 days. The total asset size of the fund is 1.878 billion CNY, with the best fund return during his tenure being 40.38% and the worst being -4.07% [3]

Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company based in Yantai, Shandong, China, established on July 4, 2008, and listed on March 31, 2022 [2] - The company focuses on the development and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADC), fusion proteins, and monoclonal antibodies, targeting significant diseases such as autoimmune diseases, tumors, and ocular diseases [2] - The main revenue sources are from product sales (99.46%), with minor contributions from material sales (0.38%) and leasing services (0.16%) [2] Financial Performance - For the first half of 2025, Rongchang Biopharmaceuticals reported a revenue of 1.098 billion yuan, representing a year-on-year growth of 48.02% [3] - The net profit attributable to the parent company was -450 million yuan, showing a year-on-year increase of 42.40% [3] Stock Performance - As of September 12, the stock price of Rongchang Biopharmaceuticals was 107.95 yuan per share, with a year-to-date increase of 258.52% [1] - The stock has seen a 17.12% increase over the last five trading days, a 40.21% increase over the last 20 days, and a 71.84% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on June 26, where it recorded a net buy of -137 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 12,900, a rise of 90.69% [3] - The average number of circulating shares per shareholder decreased by 47.56% to 12,595 shares [3] - Notable new institutional shareholders include Hong Kong Central Clearing Limited and several mutual funds, indicating growing institutional interest [4]

华泰柏瑞上证科创板综合ETF联接A（023741）成立日期2025年4月18日，最新规模6142.92万。成立以 来收益27.55%。 华泰柏瑞上证科创板综合ETF联接A（023741）基金经理为谭弘翔。 截至发稿，谭弘翔累计任职时间4年187天，现任基金资产总规模273.42亿元，任职期间最佳基金回报 78.18%， 任职期间最差基金回报-37.2%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 9月11日，荣昌生物涨5.06%，截至发稿，报108.37元/股，成交10.22亿元，换手率6.32%，总市值610.78 亿元。 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业务涉及公司是一家具有全球 化视野的创新型生物制药企业,自成立以来一直专注于抗体药物偶联物(ADC)、抗体融合蛋白、单抗及 双抗等治疗性抗体药物领域。公 ...

Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company focused on antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [2] - The company aims to discover, develop, and commercialize innovative and best-in-class biopharmaceuticals to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [2] - Main business revenue composition: 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] Financial Performance - As of June 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.098 billion yuan, a year-on-year increase of 48.02% [3] - The net profit attributable to shareholders was -450 million yuan, reflecting a year-on-year growth of 42.40% [3] Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased to 12,900, up by 90.69%, while the average circulating shares per person decreased by 47.56% [3] - The stock price of Rongchang Biopharmaceuticals has increased by 187.28% year-to-date, with a recent decline of 4.82% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on June 26, where it recorded a net buy of -137 million yuan [1] Institutional Holdings - As of June 30, 2025, notable new institutional shareholders include Hong Kong Central Clearing Limited, Wanjiayouxuan, and ICBC Frontier Medical Stock A [4] - The top ten circulating shareholders include various funds, with some showing significant changes in holdings compared to the previous period [4]